liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial
Addenbrookes Hospital, England.
Addenbrookes Hospital, England.
Maastricht University, Netherlands.
IZZ Immunol Zentrum, Switzerland.
Show others and affiliations
2015 (English)In: Annals of the Rheumatic Diseases, ISSN 0003-4967, E-ISSN 1468-2060, Vol. 74, no 6, 1178-1182 p.Article in journal (Refereed) Published
Abstract [en]

Objectives The RITUXVAS trial reported similar remission induction rates and safety between rituximab and cyclophosphamide based regimens for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis at 12months; however, immunosuppression maintenance requirements and longer-term outcomes after rituximab in ANCA-associated renal vasculitis are unknown. Methods Forty-four patients with newly diagnosed ANCA-associated vasculitis and renal involvement were randomised, 3:1, to glucocorticoids plus either rituximab (375mg/m(2)/weekx4) with two intravenous cyclophosphamide pulses (n=33, rituximab group), or intravenous cyclophosphamide for 3-6months followed by azathioprine (n=11, control group). Results The primary end point at 24months was a composite of death, end-stage renal disease and relapse, which occurred in 14/33 in the rituximab group (42%) and 4/11 in the control group (36%) (p=1.00). After remission induction treatment all patients in the rituximab group achieved complete B cell depletion and during subsequent follow-up, 23/33 (70%) had B cell return. Relapses occurred in seven in the rituximab group (21%) and two in the control group (18%) (p=1.00). All relapses in the rituximab group occurred after B cell return. Conclusions At 24months, rates of the composite outcome of death, end-stage renal disease and relapse did not differ between groups. In the rituximab group, B cell return was associated with relapse. Trial registration number ISRCTN28528813.

Place, publisher, year, edition, pages
BMJ Publishing Group , 2015. Vol. 74, no 6, 1178-1182 p.
Keyword [en]
B cells; Cyclophosphamide; Granulomatosis with polyangiitis; Systemic vasculitis; Treatment
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-119234DOI: 10.1136/annrheumdis-2014-206404ISI: 000354371200034PubMedID: 25739829OAI: oai:DiVA.org:liu-119234DiVA: diva2:821278
Note

Funding Agencies|Cambridge University Hospitals National Health Service Foundation Trust; Cambridge Biomedical Research Centre; F Hoffmann-La Roche; New Investigator award from the Kidney Research Scientist Core Education and National Training Program

Available from: 2015-06-15 Created: 2015-06-12 Last updated: 2015-06-15

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Segelmark, Mårten
By organisation
Division of Drug ResearchFaculty of Medicine and Health SciencesDepartment of Nephrology
In the same journal
Annals of the Rheumatic Diseases
Clinical Medicine

Search outside of DiVA

GoogleGoogle ScholarTotal: 1 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 71 hits
ReferencesLink to record
Permanent link

Direct link